Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurochem ; 74(4): 1621-6, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10737620

ABSTRACT

To examine the correlation between the structure of Bcl-2 and its inhibitory function of c-Jun N-terminal kinase (JNK) and caspase activity, we established a dopaminergic neuronal cell line, MN9D overexpressing Bcl-2 (MN9D/Bcl-2) or its structural mutants. The mutants comprised a point mutation in the BH1 (G145A; MN9D/BH1) or BH2 (W188A; MN9D/BH2) domain and a deletion mutation in the C-terminal (MN9D/C22), BH3 (MN9D/BH3), or BH4 (MN9D/BH4) domain. As determined by the TUNEL (terminal deoxynucleotidyltransferase nick end-labeling) and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay, apoptotic death of MN9D/Neo cells reached 80-90% within 24 h in response to 1 microM staurosporine. Upon staurosporine treatment, JNK activity increased six- to sevenfold over the basal level within 2-4 h. Treatment of MN9D/Neo with both staurosporine and a caspase inhibitor, Z-VAD, attenuated cell death without suppressing JNK activation. Both staurosporine-induced cell death and JNK activation were attenuated in MN9D/Bcl-2. As determined by cleavage of poly(ADP-ribose) polymerase into 85 kDa, Bcl-2 blocked caspase activity as well. When cells overexpressing one of the Bcl-2 mutants were treated with staurosporine, death was attenuated in MN9D/BH1, MN9D/BH2, and MN9D/C22 but not in MN9D/BH3 and MN9D/BH4. Similarly, both JNK and caspase activation were blocked in MN9D/BH1, MN9D/BH2, and MN9D/C22, whereas they were not suppressed in MN9D/BH3 and MN9D/BH4. Taken together, our data indicate that there exists a close structural and functional correlation of Bcl-2 to JNK and caspase activity in staurosporine-induced dopaminergic neuronal cell death.


Subject(s)
Apoptosis/physiology , Caspases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Neurons/cytology , Neurons/enzymology , Proto-Oncogene Proteins c-bcl-2/metabolism , Apoptosis/drug effects , Cells, Cultured , Dopamine/physiology , Enzyme Inhibitors/pharmacology , Humans , In Situ Nick-End Labeling , JNK Mitogen-Activated Protein Kinases , Mutation/physiology , Parkinson Disease/metabolism , Protein Structure, Tertiary , Proto-Oncogene Proteins c-bcl-2/chemistry , Proto-Oncogene Proteins c-bcl-2/genetics , Staurosporine/pharmacology , Structure-Activity Relationship , Transfection
2.
J Neurochem ; 72(6): 2456-63, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10349855

ABSTRACT

To assess the role of Bcl-X(L) and its splice derivative, Bcl-X(S), in staurosporine-induced cell death, we used a dopaminergic cell line, MN9D, transfected with bcl-xL (MN9D/Bcl-X(L)), bcl-xS (MN9D/Bcl-X(S)), or control vector (MN9D/Neo). Only 8.6% of MN9D/Neo cells survived after 24 h of 1 microM staurosporine treatment. Caspase activity was implicated because a caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk), attenuated staurosporine-induced cell death. Bcl-X(L) rescued MN9D cells from death (89.4% viable cells), whereas Bcl-X(S) had little or no effect. Bcl-X(L) prevented morphologically apoptotic changes as well as cleavage of poly(ADP-ribose)polymerase (PARP) induced by staurosporine. It is interesting that a small Bax-immunoreactive protein appeared 4-8 h after PARP cleavage in MN9D/Neo cells. The appearance of the small Bax-immunoreactive protein, however, may be cell type-specific as it was not observed in PC12 cells after staurosporine treatment. The sequential cleavage of PARP and the appearance of the small Bax-immunoreactive protein in MN9D cells were blocked either by Z-VAD-fmk or by Bcl-X(L). Thus, our present study suggests that Bcl-X(L) but not Bcl-X(S) prevents staurosporine-induced apoptosis by inhibiting the caspase activation that may be directly or indirectly responsible for the appearance of the small Bax-immunoreactive protein in some types of neurons.


Subject(s)
Apoptosis/physiology , Caspase Inhibitors , Dopamine/metabolism , Neurons/metabolism , Poly(ADP-ribose) Polymerases/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins/metabolism , Staurosporine/pharmacology , Animals , Apoptosis/drug effects , Cell Line , Cycloheximide/pharmacology , Kinetics , Mice , Neurons/cytology , Neurons/drug effects , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/genetics , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , Transfection , bcl-2-Associated X Protein , bcl-X Protein
3.
Neurosci Lett ; 238(3): 95-8, 1997 Dec 05.
Article in English | MEDLINE | ID: mdl-9464628

ABSTRACT

The naturally occurring neurotoxin, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol; SAL), has been speculated to contribute to Parkinson's disease and neuropathology of chronic alcoholism. In the present study, we found the capability of SAL to cause DNA cleavage in the presence of Cu(ll). Incubation of SAL and CuCl2 with calf thymus DNA caused strand breaks. Likewise, SAL in combination with Cu(ll) mediated the strand scission in øX174 RFI supercoiled DNA in a time-related manner. Neither Cu(ll) nor the catechol alone induced any appreciable DNA cleavage. The reaction of SAL with Cu(ll) was accompanied by the reduction of Cu(ll) to Cu(I). Furthermore, SAL induced cell death in cultured PC12 cells, which was exacerbated by Cu(ll). From these data, it seems likely that SAL undergoes redox cycling catalyzed by Cu(ll) to generate reactive species which may be responsible for the neurotoxic action of this catechol isoquinoline.


Subject(s)
Copper/pharmacology , DNA Damage/drug effects , Isoquinolines/pharmacology , Animals , Cell Death/drug effects , Oxidation-Reduction , PC12 Cells/drug effects , Rats , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...